Lanreotide Autogel 120 mg + Temozolomide (TMZ)
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastroenteropancreatic Neuroendocrine Tumors
Conditions
Gastroenteropancreatic Neuroendocrine Tumors
Trial Timeline
Oct 1, 2014 → Jun 1, 2017
NCT ID
NCT02231762About Lanreotide Autogel 120 mg + Temozolomide (TMZ)
Lanreotide Autogel 120 mg + Temozolomide (TMZ) is a phase 2 stage product being developed by Ipsen for Gastroenteropancreatic Neuroendocrine Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT02231762. Target conditions include Gastroenteropancreatic Neuroendocrine Tumors.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02231762 | Phase 2 | Completed |
Competing Products
9 competing products in Gastroenteropancreatic Neuroendocrine Tumors
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide. | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Famitinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| 68Ga-DOTATOC | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Lanreotide + Pembrolizumab | Merck | Phase 1/2 | 41 |
| Lutathera + Gallium 68 Dotatate | Novartis | Phase 1 | 33 |
| Lutathera® | Novartis | Pre-clinical | 23 |
| Pasireotide LAR followed by Pasireotide LAR + Everolimus + Everolimus followed by Pasireotide LAR + Everolimus | Novartis | Phase 1 | 33 |
| satoreotide trizoxetan | Ipsen | Phase 1/2 | 38 |
| Lanreotide autogel | Ipsen | Phase 3 | 74 |